CN112566909A - 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途 - Google Patents

3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途 Download PDF

Info

Publication number
CN112566909A
CN112566909A CN201980052852.6A CN201980052852A CN112566909A CN 112566909 A CN112566909 A CN 112566909A CN 201980052852 A CN201980052852 A CN 201980052852A CN 112566909 A CN112566909 A CN 112566909A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
group
compound
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980052852.6A
Other languages
English (en)
Other versions
CN112566909B (zh
Inventor
王友鑫
曲振林
张玲玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Lidao Medicine Technology Co ltd
Original Assignee
Shanghai Lidao Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Lidao Medicine Technology Co ltd filed Critical Shanghai Lidao Medicine Technology Co ltd
Publication of CN112566909A publication Critical patent/CN112566909A/zh
Application granted granted Critical
Publication of CN112566909B publication Critical patent/CN112566909B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

公开了3‑芳氧基‑3‑五元杂芳基‑丙胺类化合物及其用途。具体地公开了一种化合物，或其药学上可接受的盐、或其前药，所述化合物具有式I结构。所述的化合物，或其药学上可接受的盐、或其前药对瞬时受体电位通道蛋白(TPR)具有优异的抑制作用，并对瞬时受体电位通道蛋白相关的疾病具有良好的治疗作用。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201980052852.6A 2018-08-17 2019-08-15 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途 Active CN112566909B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810942562 2018-08-17
CN2018109425626 2018-08-17
CN201910411311X 2019-05-16
CN201910411311 2019-05-16
PCT/CN2019/100846 WO2020035040A1 (zh) 2018-08-17 2019-08-15 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途

Publications (2)

Publication Number Publication Date
CN112566909A true CN112566909A (zh) 2021-03-26
CN112566909B CN112566909B (zh) 2023-01-03

Family

ID=69525149

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980052852.6A Active CN112566909B (zh) 2018-08-17 2019-08-15 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途

Country Status (5)

Country Link
US (1) US20210332035A1 (zh)
EP (1) EP3838899A4 (zh)
JP (1) JP7272709B2 (zh)
CN (1) CN112566909B (zh)
WO (1) WO2020035040A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943943A (zh) * 2019-05-16 2020-11-17 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
CN116063281A (zh) * 2023-03-01 2023-05-05 中国科学技术大学 作为配体门控离子通道受体调节剂的一种化合物及其制备和应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020035070A1 (zh) * 2018-08-17 2020-02-20 漳州片仔癀药业股份有限公司 3-芳氧基-3-芳香基-丙胺类化合物及其用途
CN114206859B (zh) * 2019-05-16 2024-05-28 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
EP4105212A4 (en) * 2020-02-14 2024-03-06 Zhangzhou Pien Tze Huang Pharm PREPARATION METHOD AND CRYSTAL FORM OF FIVE-MEMBERED HETEROARYL-PROPYLAMINE COMPOUND 3-ARYLOXY-3
CN112794860B (zh) * 2021-03-24 2021-06-29 上海肇钰医药科技有限公司 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途
CN115703767A (zh) * 2021-08-12 2023-02-17 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法
WO2023133502A1 (en) * 2022-01-07 2023-07-13 The Johns Hopkins University Treatment and prevention of trigeminal neuralgia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094262A1 (en) * 2001-05-18 2002-11-28 Eli Lilly And Company Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
CN107840845A (zh) * 2016-09-19 2018-03-27 上海璃道医药科技有限公司 胺类化合物的新用途
WO2018115069A1 (en) * 2016-12-20 2018-06-28 Laboratorios Del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037932B2 (en) * 2001-05-18 2006-05-02 Eli Lilly And Company Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors
WO2008077645A1 (en) * 2006-12-22 2008-07-03 Synthon B.V. Process for making duloxetine and related compounds
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
US8362025B2 (en) 2008-12-22 2013-01-29 Hydra Biosciences, Inc. Compositions useful for treating disorders related to TRPA1
EP2332930A1 (en) * 2009-11-23 2011-06-15 Laboratorios Del. Dr. Esteve, S.A. Salts of duloxetine and NSAIDs for the treatment of pain
CN105497019A (zh) * 2014-09-25 2016-04-20 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物治疗疼痛的医药用途
CN107151241B (zh) * 2016-03-03 2020-12-04 中国人民解放军军事医学科学院毒物药物研究所 新的胺类化合物及其治疗抑郁症的用途
CN107625762B (zh) * 2016-07-25 2021-11-19 上海璃道医药科技有限公司 萘环类药物的新用途
EP3339304A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Quinoline and isoquinoline derivatives for treating pain and pain related conditions
WO2020035070A1 (zh) * 2018-08-17 2020-02-20 漳州片仔癀药业股份有限公司 3-芳氧基-3-芳香基-丙胺类化合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094262A1 (en) * 2001-05-18 2002-11-28 Eli Lilly And Company Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
CN107840845A (zh) * 2016-09-19 2018-03-27 上海璃道医药科技有限公司 胺类化合物的新用途
WO2018115069A1 (en) * 2016-12-20 2018-06-28 Laboratorios Del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
J. R. BOOT ET AL: ""Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
J. R. BOOT ET AL: ""Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 14, 9 September 2004 (2004-09-09), pages 5395 *
JOHN R. CASHMAN ET AL: ""Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression"", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
JOHN R. CASHMAN ET AL: ""Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression"", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 17, 20 August 2009 (2009-08-20), pages 6890, XP026601536, DOI: 10.1016/j.bmc.2009.08.025 *
张艳平等: ""度洛西汀衍生物的设计、合成及抗抑郁活性"", 《药学学报》 *
张艳平等: ""度洛西汀衍生物的设计、合成及抗抑郁活性"", 《药学学报》, vol. 45, no. 7, 31 December 2010 (2010-12-31), pages 869 - 871 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943943A (zh) * 2019-05-16 2020-11-17 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
CN116063281A (zh) * 2023-03-01 2023-05-05 中国科学技术大学 作为配体门控离子通道受体调节剂的一种化合物及其制备和应用
CN116063281B (zh) * 2023-03-01 2023-11-21 中国科学技术大学 作为配体门控离子通道受体调节剂的一种化合物及其制备和应用

Also Published As

Publication number Publication date
JP2021534248A (ja) 2021-12-09
EP3838899A4 (en) 2022-02-16
CN112566909B (zh) 2023-01-03
EP3838899A1 (en) 2021-06-23
WO2020035040A1 (zh) 2020-02-20
JP7272709B2 (ja) 2023-05-12
US20210332035A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CN112566909B (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途
WO2020035070A1 (zh) 3-芳氧基-3-芳香基-丙胺类化合物及其用途
AU2014236719B2 (en) Compounds and methods for inducing chondrogenesis
CN108558831B (zh) 取代吡咯-4-烷基胺类化合物及其用途
JP4599347B2 (ja) グルカゴンレセプターアンタゴニストとしての置換３−シアノチオフェンアセトアミド
JP2017538676A (ja) ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤
JP2013531667A (ja) 抗炎症剤、免疫調節剤及び抗増殖剤としての新規塩
CN111943943A (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
CN114206859A (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
EP3470404A1 (en) Five-membered heterocyclic derivative, method for producing same, and pharmaceutical composition comprising same
AU2022306038A1 (en) 3,4-methylenedioxymethamphetamine and related psychedlics and uses thereof
CN114149386A (zh) 芳基戊二烯酰胺类醛脱氢酶抑制剂、其合成方法及用途
WO2021160134A1 (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型
AU2017239419B2 (en) Benzenesulfonyl-asymmetric ureas and medical uses thereof
JP2021505573A (ja) ベータ−２選択的アドレナリン性受容体アゴニスト
JP6078153B2 (ja) チアンジンアミド誘導体、並びにその医薬組成物及び使用
CN117529474A (zh) N-取代苯基磺酰胺类化合物及其用途
WO2022119928A1 (en) Imidazole compounds as inhibitors of enpp1
KR20140120903A (ko) 여포 자극 호르몬수용체의 아고니스트로서 중수소화 티아졸리디논 유사체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CB03 Change of inventor or designer information

Inventor after: Wang Youxin

Inventor after: Zhang Lingling

Inventor before: Wang Youxin

Inventor before: Qu Zhenlin

Inventor before: Zhang Lingling

CB03 Change of inventor or designer information